Trials / Recruiting
RecruitingNCT07371455
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 76 (estimated)
- Sponsor
- Longwood Pharmaceuticals (Hangzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study is a randomized, double-blind, placebo-controlled clinical trial featuring both single ascending dose (SAD), food effect and multiple ascending dose (MAD) phases intended to evaluate the safety, tolerability, PK, PD, and active metabolites of LWP779 after oral administration in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LWP779 | Active |
| DRUG | Placebo of LWP779 | Placebo |
Timeline
- Start date
- 2026-03-13
- Primary completion
- 2026-07-10
- Completion
- 2026-09-30
- First posted
- 2026-01-28
- Last updated
- 2026-03-20
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07371455. Inclusion in this directory is not an endorsement.